Accessibility Tools

Skip to main content

Author: Greenleaf

Greenleaf Advancement is the provider of Greenleaf ONE, the Open Nonprofit Engine to drive organizational growth.

White paper on ‘Integrative Oncology and Wellbeing in Cancer Care’

Congratulations to Judith Lacey, SIO Global Task Force Member and Board of Trustee, for contributing to the launch of the white paper on ‘Integrative Oncology and Wellbeing in Cancer Care’. Watch the live interview with A/Prof Judith Lacey and Consumer Advocate Barry Du Bois discuss the benefits of Integrative Oncology on Studio 10 here!

 

You can find the link to the paper here: https://bit.ly/3hBsqll

Open Access: Exploring the Roles of Patient Advocates in Integrative Oncology

Exploring the Roles of Patient Advocates in Integrative Oncology
Julie Deleemans, Jodi MacLeod, Eileen Fuentes, Lesley Glenn, Elizabeth Glosik, Jenny Leyh, Susan Ryan, Marianne Sarcich, and Laura Pole

The second column by SIO Leadership in the Journal of Integrative and Complementary Medicine (JICM), features, “Exploring the Roles of Patient Advocates in Integrative Oncology”, by the SIO Patient Advocate Committee. The paper is available Open Access through March 3, 2023 here

Read the article here. 

Open Access: How Integrative Oncology is Transforming Cancer Care

The Executive Committee of the Society for Integrative Oncology is highlighted in the latest OpenAccessGov publication, discussing how integrative oncology is changing the way cancer care is provided.

Follow the link to learn more: https://www.openaccessgovernment.org/integrative-oncology-transforming-cancer-care-patients/150645/

 

Jan 5, 2023

New Member Only Webinar Recording Now Available!

Cross-cultural perspectives on the role of integrative oncology in palliative care

February 8, 2023

Members, click here to watch the webinar. Not a member? Join today and gain access to our member’s only recordings! 

The webinar will present a cross-cultural perspective to integrative oncology from East-Asia, India, and the Middle East. Drs. Eran Ben-Arye and Dr. Lorenzo Cohen will co-chair the session guided by a real clinical case. Dr. Kenji Watanabe from Japan will present the Kampo medicine approach; Dr. Rammanohar Puthiyedath from South-India will present the Ayurveda perspective; and Dr. Maryam Rassouli from Iran will present the unique Iranian Medicine perspective. Dr. Orit Gressel from Israel will present her own narrative as the integrative oncology physician who treated the patient on her long journey. Each of the speakers will address the patient-centered approach that includes the psycho-spiritual perspective. Audience participation will be encouraged. This webinar provides a wonderful opportunity to learn from practitioners across the world in order to improve the lives of those with cancer.

New SIO/ ASCO Pain Guidelines Released

FOR IMMEDIATE RELEASE:
CONTACT: Hanna Hayden
September 19, 2022 hhayden@thereisgroup.com

New recommendations address the use of integrative therapies for pain management in cancer populations
The joint practice guideline results from a partnership between the Society for Integrative Oncology and the American Society of Clinical Oncology

 

WASHINGTON, D.C. (September 19, 2022)—A new joint practice guideline from the Society for Integrative Oncology (SIO) and the American Society of Clinical Oncology, Inc. (ASCO®) has been published to address gaps in healthcare providers’ knowledge of how to safely and effectively treat common cancer symptoms and side effects using integrative medicine approaches.

“Pain is a clinical challenge for many oncology patients and clinicians, and there’s a growing body of evidence showing that integrative therapies can be useful in pain management. But to date there has not been clear clinical guidance about when and when not to use these approaches,” said Heather Greenlee, ND, PhD, co-chair of the SIO Clinical Practice Guideline Committee.

SIO joined forces with ASCO to develop a clinical practice guideline on the use of integrative therapies and pain management, building off of ASCO’s existing guideline focused on cancer pain. “This new guideline takes a deeper dive on the use of integrative therapies, which is important because clinicians and patients need to have access to the latest evidence-based information to make clinical decisions,” said Jun J. Mao, MD, MSCE, co-chair of the SIO-ASCO guideline on use of integrative therapies for pain management.

Integrative oncology is a patient-centered, evidence-informed field of cancer care that utilizes mind and body practices, natural products, and/or lifestyle modifications from different traditions alongside conventional cancer treatments. Integrative oncology aims to optimize health, quality of life, and clinical outcomes across the cancer care continuum and to empower people to prevent cancer and become active participants before, during, and beyond cancer treatment.

“Practice guidelines are a critical way to ensure healthcare providers use treatments that are based on quality evidence from scientific studies that have shown the treatment to be effective and safe,” said Immediate Past Chair of the ASCO® Evidence-Based Medicine Committee, Scott T. Tagawa, MD, MS, FACP. “The guidelines focus on important concerns in patient care that greatly impact quality of life and will help equip the oncology community with the essential knowledge needed to manage integrative therapy approaches.”

The SIO-ASCO guideline was developed following a rigorous review of published literature, including literature only from randomized clinical trials—the gold standard in healthcare research. A large panel of oncology experts was convened, co-chaired by Jun J. Mao, MD, MSCE, of Memorial Sloan Kettering Cancer Center representing SIO, and Eduardo Bruera, MD, of MD Anderson Cancer Center representing ASCO. The panel reviewed existing evidence and assessed the quality of studies; once consensus was reached, recommendations were made based on the strength of the evidence available.

Among the guideline’s strongest recommendations are that acupuncture be offered to breast cancer patients experiencing joint pain related to the use of a medication common in breast oncology called aromatase inhibitors. Because there was moderately strong evidence supporting its effectiveness and its low risk of harm, the expert panel also recommended acupuncture for general cancer pain or musculoskeletal pain as well as for chemotherapy-induced peripheral neuropathy.

The guideline also recommends the use of massage therapy for patients in palliative care or hospice who are experiencing pain.

“Clinician uptake of evidence-based treatments is always a concern, which is one of the reasons why we create practice guidelines,” said Dr. Bruera. “We are hoping that by showing the growing evidence that is out there, healthcare systems will start hiring these kinds of practitioners and insurance systems will start covering these treatments, because more and more, these are being shown to be effective at managing pain for cancer populations.”

Because the expert panel was conservative in making their recommendations, the guideline also includes areas identified as potentially relevant to cancer care but needing more research. This distinction is important because the lack of endorsement for a given therapy is not an indication that the therapy is necessarily ineffective or unsafe. Rather, it indicates that the expert panel felt the evidence was insufficient to support its recommendation. For instance, said Dr. Greenlee, more studies are needed to assess the safety and effectiveness of natural products.

To ensure patients can play a role in the treatment decision-making process and to inform their discussions about integrative therapies with their oncologists, ASCO and SIO have also posted a listing of integrative medicine patient resources on their respective websites.

“This is the first of three evidence-based guidelines for adults that SIO and ASCO are developing together, which combines the strengths of these two organizations,” added Linda E. Carlson, PhD, President of SIO. “The goal of this important collaboration is to inform as many clinicians and patients as possible about where the evidence for integrative therapies lies to support the best clinical outcomes possible for all cancer patients. And we believe this new guideline accomplishes that.”

SIO received an unrestricted grant to fund guideline development from the Samueli Foundation.

###

ASCO® is a registered trademark of the American Society of Clinical Oncology, Inc. and is used with permission. ASCO is not a partner or affiliate of SIO and does not recommend or endorse any organization, product, or service.

About The Society for Integrative Oncology:
Founded in 2003, SIO is the premier multi-disciplinary international professional organization for integrative oncology. The mission of the SIO is to advance evidence-based, comprehensive, integrative healthcare to improve the lives of people affected by cancer. SIO enables communication, education, and research to occur by bringing together practitioners and researchers across professions focused on the care of cancer patients and survivors. Members share the common goals of excellent comprehensive patient care, enhancement of anti-cancer therapy, supportive care, and prevention of cancer. SIO members are part of a unique multidisciplinary community of oncologists, nurses, psychologists, social workers, nutritionists, complementary therapy practitioners, naturopathic doctors, acupuncturists, massage therapists, epidemiologists, researchers, and many other health care practitioners. Learn more at https://integrativeonc.org/, and follow us on Facebook, Twitter, LinkedIn, Instagram, and YouTube.

Your Life and Cancer 2022 | 29-30 Jan and 12-13 Feb 2022

29-30 Jan and 12-13 Feb 2022

www.YourLifeandCancer.com

Designed for anyone who is affected by cancer, Your Life and Cancer 2022 aims to introduce you to the growing world of Integrative Medicine, combining lifestyle, complementary and conventional approaches.

Held over two weekends 29-30 Jan and 12-13 Feb 2022, Your Life and Cancer features doctors, oncologists, therapists, best-selling authors and case studies from people who have benefited from taking an integrative approach.

More than 40 cancer care experts from around the world will be online to share their knowledge and expertise and provide you with tools to improve health and vitality, help manage side effects, build resilience, manage stress & anxiety and reduce the risk of recurrence.

Register for just £40 per weekend: www.YourLifeandCancer.com/register

SIO Members can register using a discount code. To access the discount code, please log in using your SIO log in credentials.

Find out more: www.YourLifeandCancer.com

Message to the SIO Community

May 22, 2023

Dear SIO Community,

The Society for Integrative Oncology is an international nonprofit organization established 20 years ago to advance evidence-based, comprehensive integrative healthcare to improve the lives of people affected by cancer. We are staffed by a group of volunteer healthcare providers, researchers, and patient advocates. Due to our volunteerism business model, it is necessary to outsource full time management of our business which includes finance, accounting, human resources, event planning, legal and other needs. Since inception, SIO has frequently relied on third-party consultancy firms specializing in nonprofit management for these tasks. In 2020, the consultancy firm of Hauck & Associates (“H&A”) in Washington, DC was selected as its outside management company after completing background checks and reviewing references. H&A started in that role on January 1, 2021.  

On May 10, 2023, we learned that Graham Hauck, the principal manager at H&A, pleaded guilty in federal court to misappropriation of funds of another nonprofit organization managed by H&A. SIO quickly terminated H&A, and initiated a series of risk management measures, including securing its assets to prevent further losses; retrieving paper and electronic files and financial books and records; revoking Hauck’s access to bank accounts, internet sites, keys, credit cards and the like; arranging for new management, accounting and operations solutions to replace H&A; hiring a forensic accountant, Chess Consulting LLC, to detect any misappropriation of SIO funds and determine the amount involved; and retaining as outside counsel white collar criminal attorney, Zach Hafer at Cooley LLP (formerly with the US Attorney’s Office), Michael Sanders, a tax exempt tax attorney and professor at Georgetown Law Center and his partner, Malcolm Sandilands, a corporate attorney, both at Blank Rome LLP. We are working with conference specialists in Canada to ensure that our Banff 2023 conference is not disrupted by these developments, and with other specialists to ensure that the SIO’s other activities continue with the minimum possible adverse impact.  

Internally, SIO has appointed its first general counsel, Nelson Lin, to coordinate our legal response, which includes crisis management and supervision of recovery, while the Executive Committee of the Board of Trustees has worked continuously since learning of Hauck’s guilty plea to transfer every single management function out of his firm’s hands. That process continues, and we will make every effort to secure the return of any funds that were misappropriated from SIO; our criminal counsel has reached out to Hauck to pursue prompt restitution of any misappropriated funds.

The Board of Trustees will report progress biweekly to SIO members as it continues to investigate this matter.

We thank you for your understanding and patience and we will continue to do everything we can to resolve this in an expeditious and efficient manner. 

 Sincerely

Linda Ellen Carlson, PhD, RPsych 

President, Society for Integrative Oncology, Inc.

Guideline provides recommendations for integrative approaches to manage cancer pain

Check out Jun Mao, MD, Chief of Integrative Medicine at Memorial Sloan Kettering Cancer Center and author of the guidelines, Integrative Medicine for Pain Management in Oncology, as he speaks on the importance of the study and the implications of the findings. 

Watch the interview here.

Announcement of SIO/ASCO collaboration on two more evidence based guidelines in 2021-22

“It is critical to separate evidence-based, integrative health approaches from those without evidence,” said Ting Bao, MD, DAMBA, MS, president of SIO. “These guidelines will help the cancer community ensure safe, effective use of integrative approaches for managing patients’ cancer-related symptoms.”

The majority of people with cancer seek out integrative therapies sometime after receiving their diagnosis. Integrative health approaches during cancer care are patient-centered treatments that utilize evidence-informed mind and body practices, natural products, and/or lifestyle modifications from various traditions, alongside conventional cancer treatments.

“We are delighted to collaborate with SIO on the development of evidence-based guidelines that will help optimize the care of patients with cancer using therapies complementary to cancer treatment,” said Chair of the ASCO® Clinical Practice Guidelines Committee, Douglas E. Peterson, DMD, PhD. “The guidelines will focus on important concerns in patient care that greatly impact quality of life, and will help equip the oncology community with the essential knowledge needed to manage integrative therapy approaches.”

SIO and ASCO® will convene independent panels of experts representing members of both societies to produce a series of three evidence-based guidelines for adults focusing on cancer-related pain management, fatigue in cancer survivors, and care of anxiety and depressive symptoms experienced by those with cancer. The topics were selected based on expert consensus and surveys of SIO’s membership. Each expert panel will review published literature, including systematic reviews and existing guidelines. The expert panels will outline and recommend evidence-based integrative therapies to use, as well as caution against ineffective or harmful approaches, for specific clinical indications during and after cancer treatment.

“Many patients already use integrative approaches during and after their cancer treatment, but medical decisions need to be made based on firm science,” said Heather Greenlee, ND, PhD, co-chair of SIO’s Clinical Practice Guidelines Committee. “By co-developing these clinical guidelines, SIO and ASCO® will help bring this evidence-based treatment information to patients and oncologists worldwide, so they can wisely allocate resources to the most effective complementary approaches.”

SIO received an unrestricted grant to fund guideline development from the Samueli Foundation.

ASCO® is a registered trademark of the American Society of Clinical Oncology, Inc. and is used with permission. ASCO is not a partner or affiliate of SIO and does not recommend or endorse any organization, product, or service.

About The Society for Integrative Oncology:
Founded in 2003, SIO is the premier multi-disciplinary international professional organization for integrative oncology. The mission of the SIO is to advance evidence-based, comprehensive, integrative healthcare to improve the lives of people affected by cancer. SIO enables communication, education, and research to occur by bringing together practitioners and researchers across professions focused on the care of cancer patients and survivors. Members share the common goals of excellent comprehensive patient care, enhancement of anti-cancer therapy, supportive care, and prevention of cancer. SIO members are part of a unique multidisciplinary community of oncologists, nurses, psychologists, social workers, nutritionists, complementary therapy practitioners, naturopathic doctors, acupuncturists, massage therapists, epidemiologists, researchers, and many other health care practitioners. Learn more at https://integrativeonc.org/, and follow us on Facebook, Twitter, LinkedIn, and YouTube. 

FOR IMMEDIATE RELEASE: CONTACT: Tamara Moore, 202-868-4008
October 27, 2020 tmoore@thereisgroup.com

SIO to Work with Leading Oncology Society on Guidelines for Integrative Approaches for Cancer Care
Medical societies to develop three evidence-based clinical practice guidelines in 2021

WASHINGTON (October 27, 2020) – The Society for Integrative Oncology announced today that it is collaborating with the American Society of Clinical Oncology, Inc. (ASCO®), the world’s leading professional organization of its kind representing oncology professionals who care for people living with cancer, to develop a series of evidence-based clinical practice guidelines for integrative therapies in oncology care. The guidelines, planned for publication in 2021 and 2022, will provide clinicians and patients much-needed guidance on safely and effectively treating common cancer symptoms and side effects using integrative approaches.

Navajo Nation’s Regional Healthcare Facility Needs Our Help

The current COVID-19 pandemic has acutely affected the Navajo Nation, which lives in a region spanning parts of Arizona, Utah and New Mexico. Historically, the Navajo People have suffered high rates of diabetes, cardiovascular disease and cancer, all of which contribute to increased risk for poorer COVID-19 outcomes.

For decades, tribal land has been left without basic infrastructure such as running water, electricity and paved roads.

The Indian Health Service has been chronically underfunded, and the Tuba City Regional Healthcare Corporation is the only cancer treatment location on any Native American soil. The SIO is honored to present this support initiative. Donations will go directly to Tuba City Regional Healthcare through the Cancer Support Community donation page, and will be used for essential healthcare needs such as PPE for staff and hand sanitizer. Please join us in this opportunity to improve the lives of those who suffer such health disparities. Learn  more on our COVID-19 Resources page and submit your contribution on our Donation page.

SIO and UBM Medica’s ONCOLOGY Journal Announce Partnership

Through this partnership, SIO will gain significant reach into the cancer-treatment community through UBM Medica’s oncology distribution channels – the ONCOLOGY journal and CancerNetwork.com – allowing SIO members greater access to information impacting the field of oncology as well as their day-to-day clinical practice.

In turn, with the addition of one of SIO’s key thought leaders to its respected editorial advisory board, the ONCOLOGY journal will be able to provide more relevant integrative oncology information to its readership, furthering SIO’s mission to advance evidence-based, comprehensive, integrative healthcare to improve the lives of people affected by cancer.

 “We are very excited to enter in to this partnership with SIO, which will not only allow the ONCOLOGY journal to offer a greater breadth of information on integrative oncology, but it will increase SIO’s visibility and impact in the oncology field,” said Nora Ray, Editorial Director of Oncology at UBM Medica. “This benefits the members of SIO and ONCOLOGY’s readership alike.”

About SIO: About the Society for Integrative Oncology: The Society for Integrative Oncology is the leading worldwide organization dedicated to integrative medicine specific to cancer patients. A non-profit, multi-disciplinary organization founded in 2003, the organization’s mission is to advance evidence-based, comprehensive, integrative healthcare to improve the lives of people affected by cancer. For more information, visit www.integrativeonc.org.

About UBM Medica: UBM Medica provides unbiased clinical, practical, and business information to over 1 million healthcare providers, resulting in improved quality of care for patients around the world.  We serve our clients in the pharmaceutical, medical device, and related industries by delivering strategic, integrated communications solutions at the point of patient care – whether online, mobile, or in print. Our reach extends to practitioners and decision makers in primary care, pediatrics, cancer care, psychiatry, dermatology, endocrinology, eye care, neurology, women’s health, men’s health, radiology, managed care, pharmacy, and more. For more information, visit www.ubmmedica.com.

onc july cover 250 1UBM Medica, a leading provider of educational resources to healthcare professionals, and SIO have begun a partnership to offer SIO members access to ONCOLOGY journal and CancerNetwork.com as a benefit of membership. Through the partnership, SIO also will provide content on integrativeoncology.

December Herb of the Month: Mistletoe

Mistletoe extracts are used to treat a variety of conditions including cancer, AIDS, hepatitis, and degenerative joint disease. Preclinical studies indicate that mistletoe extracts have anticancer effects, with lectins being the active constituents. Clinical data suggest utility of mistletoe therapy, mainly in the injectable form, for improving symptoms including pain, fatigue, insomnia; and for improving quality of life in cancer patients. These findings have led to the use of mistletoe as an adjuvant treatment in some countries. However, more rigorous studies are needed to determine its potential benefits.
 
Oral preparations are marketed as dietary supplements and homeopathic remedies in the United States. But injections are not available outside of clinical trials because mistletoe is not approved for medical use by the U.S. Food and Drug Administration. Read more

This resource is provided with thanks to the Integrative Medicine Service at Memorial Sloan Kettering Cancer Center, which maintains a free web site, About Herbs.

We chose mistletoe for this month because of the continued debate over its use. A semi-parasitic plant, mistletoe grows on many species of trees native to Europe and Western Asia. The leaves and twigs have a long medicinal history, but the berries are highly poisonous.